Allergan PLC is urgently seeking guidance from the US FDA to learn what prevented its supplemental new drug application (sNDA) for Vraylar (cariprazine) to treat negative symptoms associated with schizophrenia from being filed for review.
After conveying optimism about the future of its schizophrenia drug Vraylar, which has a different mechanism of action compared to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?